The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography

Int J Rad Appl Instrum B. 1992 Feb;19(2):183-90. doi: 10.1016/0883-2897(92)90006-k.


In this study, 2-[18F]fluoro-2-deoxy-D-glucose, [( 18F]FDG) was used to radiolabel human granulocytes in vitro for possible clinical use by positron emission tomography (PET). Uptake of [18F]FDG was dependent on the amount of glucose in the labelling medium, e.g. when 1 x 10(7) granulocytes were incubated with [18F]FDG containing 15 micrograms/mL glucose 80% of [18F]FDG was incorporated within 30 min, but in the presence of 1 mg/mL of glucose it was reduced to 2%. Increasing the cell concentration and activating the granulocytes with Streptococcus pneumoniae, opsonized zymosan or phorbol myristate acetate all increased the uptake of [18F]FDG. Retention of the [18F]FDG by the cells as [18F]FDG-6-phosphate was also dependent on the extracellular glucose concentration, 9% was released within 60 min in the absence of glucose, but 27% in the presence of 1 mg/mL glucose.

MeSH terms

  • Cell Survival
  • Cells, Cultured
  • Chromatography, Thin Layer
  • Deoxyglucose / analogs & derivatives*
  • Deoxyglucose / metabolism
  • Deoxyglucose / pharmacokinetics
  • Fluorine Radioisotopes / metabolism
  • Fluorine Radioisotopes / pharmacokinetics
  • Fluorodeoxyglucose F18
  • Granulocytes / cytology
  • Granulocytes / metabolism*
  • Humans
  • Kinetics
  • Stimulation, Chemical
  • Streptococcus pneumoniae
  • Temperature
  • Tetradecanoylphorbol Acetate
  • Tomography, Emission-Computed
  • Zymosan / pharmacology


  • Fluorine Radioisotopes
  • Fluorodeoxyglucose F18
  • Zymosan
  • Deoxyglucose
  • Tetradecanoylphorbol Acetate